The Grimm lab in the Molecular Pharmacology Program focuses on the development of novel and innovative molecular imaging approaches for cancer diagnostics, predominantly based on activatable imaging agents. These approaches combine and utilize modern biology, nanotechnology, chemistry and physics with modern imaging methods (MRI, optical imaging, PET and Cerenkov) to create novel imaging agents that allow much earlier detection and improved therapy monitoring of cancer.
Jan Grimm, MD, PhD
Research FocusRadiologist Jan Grimm develops novel activatable molecular imaging approaches for improved detection and monitoring of prostate and other cancers.
- MD, University of Hamburg (Germany)
- PhD, University of Kiel (Germany)
- Photoactivatable Prodrug of Doxazolidine Targeting Exosomes. Tamura R, Balabanova A, Frakes SA, Bargmann A, Grimm J, Koch TH, Yin H. J Med Chem. 2019 Feb 13. doi: 10.1021/acs.jmedchem.8b01508.
- Sonophore-enhanced nanoemulsions for optoacoustic imaging of cancer. Roberts S, Andreou C, Choi C, Donabedian P, Jayaraman M, Pratt EC, Tang J, Pérez-Medina C, Jason de la Cruz M, Mulder WJM, Grimm J, Kircher M, Reiner T. Chem Sci. 2018 May 18;9(25):5646-5657. doi: 10.1039/c8sc01706a. eCollection 2018 Jul 7.